Low-molecular-weight heparin versus unfractionated heparin in acute ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with drug-eluting stents

Authors
Yong-Jian LiSeung-Woon RhaKang-Yin ChenKanhaiya L. PoddarZhe JinYoshiyasu MinamiLin WangQun DangGuang-Ping LiSureshkumar RamasamyJi-Young ParkChol Ung ChoiJin-Won KimEung Ju KimChang Gyu ParkHong Seog SeoDong Joo OhMyung Ho JeongYoung Keun AhnTaek Jong HongJong-Seon ParkYoung Jo KimSeung Ho HurIn Whan SeongJei Keon ChaeMyeong Chan ChoJang Ho BaeDong Hoon ChoiYang Soo JangIn Ho ChaeHyo Soo KimChong Jin KimJung Han YoonTae Hoon AhnSeung-Jea TahkWook Sung ChungKi Bae SeungSeung Jung Park
Department
Dept. of Internal Medicine (내과학); Cardiovascular Center
Issue Date
2010
Citation
American Heart Journal, Vol.159(4) : 684-690, 2010
ISSN
0002-8703
Abstract
Background Whether low-molecular-weight heparin (LMWH) is superior to unfractionated heparin (UFH) in acute STsegment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) with drug-eluting stents (DESs) remains unclear. Methods A total of 3,372 STEMI patients who underwent primary PCI with DESs received either LMWH (n = 1,531 patients, subcutaneous enoxaparin 1 mg/kg, bid for 3-5 days plus reduced dose of UFH [50 U/kg] during PCI) or UFH alone (n = 1,841 patients, intravenous bolus injection of 5,000 U, followed by 24,000 U/d infusion for at least 48 hours). The bleeding events and clinical outcomes during in-hospital and at 8 months were compared. Results The incidences of major and minor bleeding events were similar between the 2 groups. Multivariable Cox regression analysis showed that LMWH group had lower incidences of cardiac death (adjusted odds ratio [OR] 0.55, 95% CI 0.39-0.77, P b .001), total death (adjusted OR 0.50, 95% CI 0.37-0.68, P b .001), and total major adverse cardiac events (adjusted OR 0.77, 95% CI 0.62-0.95, P = .017) at 8 months as compared with UFH group. Similar results were obtained across different subgroups including different DESs, age, and sex. Conclusions The LMWH enoxaparin combined with reduced dose of UFH (50 U/kg) administration as an adjunctive antithrombotic therapy in STEMI patients undergoing primary PCI with DESs seems to be safe and efficacious. However, randomized clinical trials are needed to confirm this conclusion. (Am Heart J 2010;159:684-690.e1.)
URI
http://kumel.medlib.dsmc.or.kr/handle/2015.oak/35430
Appears in Collections:
1. Journal Papers (연구논문) > 1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
Keimyung Author(s)
허승호
Full Text
https://linkinghub.elsevier.com/retrieve/pii/S0002870310000888
File in this Item
 사서에게 요청하기
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE